Categories Earnings, Health Care

Amicus Therapeutics (FOLD): FY 2019 Earnings Snapshot

— Biotechnology company Amicus Therapeutics (NASDAQ: FOLD) reported a net loss of $356.4 million or $1.48 per share for fiscal 2019, compared to a loss of $349 million or $1.88 per share in the preceding year.

— Total revenues nearly doubled to $182.2 billion in 2019 from $91.25 million in 2018

— Adjusted operating expenses were $464.3 million in 2019, up 14% compared to fiscal 2018

— Expects revenues of Galafold, a therapy for Fabry disease in adults, to be in the range of $250 million to $260 million in fiscal 2020

— Estimates full-year operating expense to be in the range of $410 million to $420 million, which represents an increase from last year

— On track to continue ongoing operations well into 2022, making use of the current cash position

— Looks to complete Pompe Phase-3 PROPEL study, enroll pediatric studies and advance manufacturing to support 2021 BLA and MAA

Get access to timely and accurate in verbatim transcripts that are published within hours of the event

Most Popular

360 DigiTech (NASDAQ: QFIN) Q3 2021 Research Summary

The positive effects of widespread digitalization and e-commerce growth on China’s financial services industry became more pronounced during the pandemic as the movement restrictions drove more retail customers to online

Activision Blizzard (ATVI): Three reasons why this stock deserves to be on your radar

Shares of Activision Blizzard Inc. (NASDAQ: ATVI) were up 1.6% on Thursday. The stock has dropped 14% since the start of the year. The company has been in the news

IPO Alert: Here’s all you need to know about Remitly Global’s upcoming market debut

The emergence of technology-driven financial services is making people think beyond conventional banks when it comes to availing loans and transferring funds. In a move aimed at taking its business

Add Comment
Loading...
Cancel
Viewing Highlight
Loading...
Highlight
Close
Top